Tapentadolprolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistry.

Abstract

Aim: Comparison of tapentadolprolonged release (PR) with other oral WHO-III PR opioid analgesics (morphine, oxycodone±naloxone, hydromorphone) in routine medical care of chronic low back pain. Patients & methods: Noninterventional, retrospective 12-week study usinganonymized clinical practice data from the German Pain eRegistry. Six effectiveness, tolerability, and safety criteria were aggregated in a primary composite end point (treatment responder). Propensity scoring matched 2331 datasets per treatment cohort. Results: All six single criteria showed significantly better outcomes for tapentadol PR (all parameters p<0.001). There were significantly more treatment responders under tapentadol PR (65.7 vs 14.2%; p<0.001). Conclusion: Tapentadol PR showed significantly better effectiveness and tolerability in severe chronic low back pain unsuccessfully treated with WHO-I/II analgesics compared with the other oral WHO-III PR opioids investigated.